Gilead Sciences EPS - Earnings per Share 2010-2024 | GILD

Gilead Sciences earnings per share (EPS) for the twelve months ending June 30, 2024 was $0.82, a 81.11% decline year-over-year.

  • Gilead Sciences EPS for the quarter ending June 30, 2024 was $1.29, a 55.42% increase year-over-year.
  • Gilead Sciences 2023 annual EPS was $4.5, a 23.63% increase from 2022.
  • Gilead Sciences 2022 annual EPS was $3.64, a 26.17% decline from 2021.
  • Gilead Sciences 2021 annual EPS was $4.93, a 4830% increase from 2020.

Earnings per share can be defined as a company's net earnings or losses attributable to common shareholders per diluted share base, which includes all convertible securities and debt, options and warrants.

Gilead Sciences EPS - Earnings per Share 2010-2024 | GILD

  • Gilead Sciences EPS for the quarter ending June 30, 2024 was $1.29, a 55.42% increase year-over-year.
  • Gilead Sciences 2023 annual EPS was $4.5, a 23.63% increase from 2022.
  • Gilead Sciences 2022 annual EPS was $3.64, a 26.17% decline from 2021.
  • Gilead Sciences 2021 annual EPS was $4.93, a 4830% increase from 2020.

Earnings per share can be defined as a company's net earnings or losses attributable to common shareholders per diluted share base, which includes all convertible securities and debt, options and warrants.
Related Stocks
Company NameMarket
Cap
Amgen (AMGN)$173B
Vertex Pharmaceuticals (VRTX)$127.1B
Bristol Myers Squibb (BMY)$112.1B
CSL (CSLLY)$91B
Regeneron Pharmaceuticals (REGN)$89.7B
GSK (GSK)$74.4B
Argenex SE (ARGX)$35.2B
Alnylam Pharmaceuticals (ALNY)$35.2B
Biogen (BIIB)$25.4B
BioNTech SE (BNTX)$25.4B
Illumina (ILMN)$24.2B
Moderna (MRNA)$19.9B
BeiGene (BGNE)$19.7B
Incyte (INCY)$15.6B
Genmab (GMAB)$14.8B
Insmed (INSM)$13B
Vaxcyte (PCVX)$13B
BioMarin Pharmaceutical (BMRN)$12.6B
Sarepta Therapeutics (SRPT)$12.2B
Bio-Techne Corp (TECH)$12B
Exelixis (EXEL)$10.1B
Exact Sciences (EXAS)$10.1B
QIAGEN (QGEN)$10B
Revolution Medicines (RVMD)$9.9B
Intra-Cellular Therapies (ITCI)$9.5B
Bio-Rad Laboratories (BIO.B)$9.4B
Roivant Sciences (ROIV)$8.7B
Repligen (RGEN)$8.2B
Ascendis Pharma (ASND)$7.8B
Halozyme Therapeutics (HALO)$7.7B